Snapshot from Jul 01, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / UCLA Research: Creatine Boosts...
Tech medical breakthrough

UCLA Research: Creatine Boosts Cancer Immunity

Analysis based on 6 articles · First reported Jun 05, 2026 · Last updated Jun 08, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This research could significantly impact the biotechnology and pharmaceutical industries by opening new avenues for cancer immunotherapy and vaccine development. Companies involved in creatine production or cancer treatments may see increased interest and potential for new product lines, leading to positive stock performance for those who successfully integrate these findings.

Biotechnology Pharmaceuticals Healthcare
Event Summary

New research from the University of California, Los Angeles (UCLA) has revealed that creatine, a popular supplement, supercharges critical immune cells, specifically dendritic cells and T cells, enhancing the body's ability to fight cancer. The study, published in Cell Press, builds on previous work and shows that creatine boosts ATP levels in dendritic cells, helping them maintain stable energy and activate effectively in nutrient-poor tumor environments. This discovery suggests creatine could be used as a supplement to enhance existing immunotherapies and improve the potency of dendritic cell-based cancer vaccines. While promising, the findings are currently based on mouse models and human cells, with clinical trials in patients yet to be conducted. The Nigeria — Petroleum Technology Development Fund has filed a patent application for this therapeutic strategy.

Entities Involved
per
Lili Yang
Lili Yang is the senior author of the study and a professor at the University of California, Los Angeles, whose lab conducted the research. She emphasizes creatine's potential to holistically support the immune response in modern immunotherapies.
Importance 80 Sentiment 50
per
James Elsten-Brown
James Elsten-Brown is a co-first author of the study and a graduate student in Lili Yang's lab. He highlights the dual potential of creatine as a supplement for patients and a tool to improve dendritic cell-based vaccines.
Importance 70 Sentiment 40
per
Elliot Kang
Elliot Kang is a co-first author of the study and a former undergraduate student researcher in Lili Yang's lab. He emphasizes that metabolically supporting dendritic cells is crucial for the entire anti-tumor response.
Importance 70 Sentiment 40
oth
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA
The Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA is where Lili Yang is a member, indicating its involvement in supporting this type of research.
Importance 30 Sentiment 30
oth
UCLA Health Jonsson Comprehensive Cancer Center
The UCLA Health Jonsson Comprehensive Cancer Center provided funding for the study, highlighting its support for cancer research.
Importance 30 Sentiment 30
govactor
Nigeria — Petroleum Technology Development Fund
The Nigeria — Petroleum Technology Development Fund filed a patent application for the newly identified therapeutic strategy, indicating efforts to protect the intellectual property.
Importance 30 Sentiment 30
oth
Cell Press
Cell Press is the journal where the research findings on creatine and cancer immunotherapy were published, providing a platform for disseminating this scientific breakthrough.
Importance 20 Sentiment 30
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration (FDA) is mentioned as the regulatory body that has not yet approved the experimental strategies described in the study for human use, indicating the need for further clinical trials.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.